Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel Free GLMD Stock Alerts

Galmed Pharmaceuticals (GLMD) Financials

Galmed Pharmaceuticals logo
$3.99 -0.31 (-7.21%)
As of 02:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Galmed Pharmaceuticals

Annual Income Statements for Galmed Pharmaceuticals

This table shows Galmed Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -17 -12 -9.86 -20 -29 -32 -18 -6.91 -7.52 -10
Consolidated Net Income / (Loss)		 -11 -17 -12 -9.86 -20 -29 -32 -18 -6.91 -7.52 -10
Net Income / (Loss) Continuing Operations		 -11 -17 -12 -9.86 -20 -29 -32 -18 -6.91 -7.52 -10
Total Pre-Tax Income 		-11 -17 -12 -9.78 -20 -29 -32 -18 -6.91 -7.52 -10
Total Operating Income		 -11 -17 -12 -11 -22 -30 -33 -18 -7.49 -7.42 -11
Total Gross Profit		 0.00 0.47 1.09 2.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.47 1.09 2.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 17 13 13 22 30 33 18 7.49 7.42 11
Selling, General & Admin Expense		 3.25 3.08 3.80 4.44 4.20 4.13 5.66 4.66 3.92 3.30 3.64
Research & Development Expense		 7.63 14 9.65 8.31 18 26 27 13 3.57 2.98 4.87
Impairment Charge		 - - - - - - - - 0.00 1.15 2.46
Total Other Income / (Expense), net		 0.25 0.04 0.07 0.93 1.92 1.44 0.41 -0.22 0.58 -0.09 0.66
Interest Expense		 - - - - - - - - 0.00 0.61 0.08
Other Income / (Expense), net		 0.25 0.04 0.07 0.93 1.92 1.44 0.41 -0.22 0.58 0.52 0.74
Basic Earnings per Share		 - - - $0.54 $0.97 $1.35 $19.80 $127.80 $30.00 $8.08 $2.39
Weighted Average Basic Shares Outstanding		 11.10M 11.37M 12.49M 18.14M 21.11M 21.28M 1.64M 139.68K 230.80K 930.82K 4.31M
Diluted Earnings per Share		 - - - $0.54 - - $19.80 - $30.00 $8.08 $2.39
Weighted Average Diluted Shares Outstanding		 11.10M 11.37M 12.49M 18.14M 21.11M 21.28M 1.64M 139.68K 230.80K 930.82K 4.31M
Weighted Average Basic & Diluted Shares Outstanding		 11.10M 11.37M 12.49M 18.14M 21.11M 21.28M 25.09M 139.68K 5.05M 1.65M 6.58M

Quarterly Income Statements for Galmed Pharmaceuticals

No quarterly income statements for Galmed Pharmaceuticals are available.

Annual Cash Flow Statements for Galmed Pharmaceuticals

This table details how cash moves in and out of Galmed Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -20 -1.06 9.92 11 -8.12 -8.98 -4.06 -0.87 0.85 1.80 -0.66
Net Cash From Operating Activities		 -8.47 -12 -12 -9.02 -15 -26 -33 -19 -6.14 -5.88 -6.32
Net Cash From Continuing Operating Activities		 -8.47 -12 -12 -9.02 -15 -26 -33 -19 -6.14 -5.88 -6.32
Net Income / (Loss) Continuing Operations		 -11 -17 -12 -9.86 -20 -29 -32 -18 -6.91 -7.52 -10
Consolidated Net Income / (Loss)		 -11 -17 -12 -9.86 -20 -29 -32 -18 -6.91 -7.52 -10
Depreciation Expense		 0.05 0.17 0.24 0.39 0.04 0.04 0.04 0.04 0.03 0.08 0.00
Amortization Expense		 0.09 0.04 0.02 -0.14 -0.11 0.09 0.12 -0.00 0.02 -0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.80 1.95 0.02 1.26 2.16 1.29 1.86 1.78 0.59 2.30 3.07
Changes in Operating Assets and Liabilities, net		 1.21 2.66 -0.05 -0.67 3.43 1.07 -2.45 -2.45 0.13 -0.73 0.91
Net Cash From Investing Activities		 -11 6.34 6.44 -60 6.68 17 11 18 0.80 -1.11 -3.38
Net Cash From Continuing Investing Activities		 -11 6.34 6.44 -60 6.68 17 11 18 0.80 -1.11 -3.38
Acquisitions		 - - - - - - - 0.00 0.00 -0.25 0.00
Purchase of Investments		 -27 -7.62 -3.87 -92 -94 -55 -14 -2.37 -4.13 -5.12 -1.44
Sale and/or Maturity of Investments		 16 14 10 32 101 47 21 21 8.63 5.50 1.61
Other Investing Activities, net		 - - - - 0.00 24 3.80 -1.50 -3.70 -1.25 -3.55
Net Cash From Financing Activities		 0.00 4.73 16 80 0.14 0.77 17 0.07 6.19 8.79 9.03
Net Cash From Continuing Financing Activities		 0.00 4.73 16 80 0.14 0.77 17 0.07 6.19 8.79 9.03
Issuance of Common Equity		 0.00 4.48 15 79 0.00 0.71 17 0.07 6.19 8.79 9.03
Cash Interest Paid		 - - - - 1.95 1.19 0.56 0.30 0.38 0.50 0.91

Quarterly Cash Flow Statements for Galmed Pharmaceuticals

No quarterly cash flow statements for Galmed Pharmaceuticals are available.

Annual Balance Sheets for Galmed Pharmaceuticals

This table presents Galmed Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 24 16 20 91 77 52 37 17 17 19 19
Total Current Assets		 23 16 19 90 76 52 36 15 13 16 19
Cash & Equivalents		 4.16 3.10 13 24 16 6.95 2.88 2.02 2.86 4.65 3.99
Restricted Cash		 - - - 0.00 0.11 0.11 0.11 0.11 0.12 0.12 0.12
Short-Term Investments		 19 12 5.98 66 60 40 32 12 7.53 7.18 7.03
Accounts Receivable		 0.38 0.28 0.16 0.22 0.83 0.81 1.13 0.83 0.48 0.67 0.35
Other Current Assets		 - - - - - 3.81 - 0.00 2.25 3.50 7.15
Plant, Property, & Equipment, net		 0.88 0.72 0.49 0.19 0.17 0.18 0.15 0.11 0.08 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.54 0.39 0.41 1.72 3.31 2.38 0.00
Long-Term Investments		 - - - - - - 0.00 1.50 3.27 2.12 0.00
Other Noncurrent Operating Assets		 - - - 0.00 0.54 0.39 0.41 0.22 0.04 0.26 0.00
Total Liabilities & Shareholders' Equity		 24 16 20 91 77 52 37 17 17 19 19
Total Liabilities		 2.72 5.38 3.85 2.71 7.29 8.23 6.11 3.14 2.75 2.17 2.85
Total Current Liabilities		 2.54 4.58 3.85 2.71 6.93 8.01 5.88 3.09 2.75 2.17 2.85
Accounts Payable		 2.54 3.49 3.31 2.71 6.93 7.05 4.87 2.56 1.88 1.31 2.00
Other Current Liabilities		 - - - - - 0.97 1.01 0.53 0.87 0.87 0.84
Total Noncurrent Liabilities		 0.18 0.80 0.00 0.00 0.35 0.22 0.23 0.04 0.00 0.00 0.00
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 22 11 16 88 70 44 30 13 14 16 16
Total Preferred & Common Equity		 22 11 16 88 70 44 30 13 14 16 16
Total Common Equity		 22 11 16 88 70 44 30 13 14 16 16
Common Stock		 69 75 92 174 177 180 199 200 207 217 227
Retained Earnings		 -47 -64 -77 -86 -107 -136 -168 -186 -193 -200 -211
Accumulated Other Comprehensive Income / (Loss)		 -0.21 -0.09 -0.01 -0.01 0.04 0.27 -0.17 -0.75 -0.45 -0.42 -0.30

Quarterly Balance Sheets for Galmed Pharmaceuticals

No quarterly balance sheets for Galmed Pharmaceuticals are available.

Annual Metrics And Ratios for Galmed Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Galmed Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 11,100,453.00 12,149,226.00 14,435,161.00 21,018,919.00 21,139,385.00 21,325,975.00 25,088,414.00 25,203,396.00 5,045,324.00 1,654,428.00 6,581,390.00
DEI Adjusted Shares Outstanding		 61,669.00 67,496.00 80,195.00 116,772.00 117,441.00 118,478.00 139,380.00 140,019.00 420,444.00 1,654,428.00 6,581,390.00
DEI Earnings Per Adjusted Shares Outstanding		 -172.24 -251.17 -153.36 -84.40 -174.22 -242.84 -232.94 -127.60 -16.44 -4.54 -1.57
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 132.33% 87.83% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -15.25% -58.72% 27.62% 20.77% -115.25% -39.51% -12.79% 44.80% 61.52% 0.31% -49.32%
EBIT Growth		 -16.70% -58.60% 27.00% 20.47% -109.19% -40.61% -12.85% 44.97% 61.31% 0.07% -48.11%
NOPAT Growth		 -18.96% -55.24% 26.76% 13.34% -108.83% -35.01% -8.84% 46.32% 57.55% 0.92% -47.80%
Net Income Growth		 -16.69% -59.60% 27.45% 19.86% -107.60% -40.61% -12.85% 44.97% 61.31% -8.75% -37.14%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -73.07% -70.42%
Operating Cash Flow Growth		 8.30% -43.13% 0.51% 25.23% -65.54% -75.99% -25.13% 43.75% 66.83% 4.19% -7.40%
Free Cash Flow Firm Growth		 17.36% -38.05% -6.32% 12.03% -45.18% -95.44% 9.37% 31.50% 50.52% -0.16% -37.27%
Invested Capital Growth		 -614.53% -221.03% 22.02% 28.36% -150.65% 47.15% -45.84% 55.42% 105.47% 1,985.19% 106.39%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -3,561.88% -1,109.59% -468.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -3,614.99% -1,139.54% -525.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -3,607.49% -1,133.55% -479.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -3,630.19% -1,133.55% -483.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.63% 100.00% 100.77% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 108.83% 100.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -40.12% -103.94% -91.54% -19.01% -25.94% -50.47% -86.98% -81.36% -50.63% -49.77% -64.21%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,785.56% -622.04% -292.05%
Operating Return on Assets (OROA)		 0.00% -82.76% -68.15% -17.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -83.28% -68.15% -17.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -40.12% -103.94% -91.54% -19.01% -25.94% -50.47% -86.98% -81.36% -50.63% -49.77% -64.21%
Return on Equity Simple (ROE_SIMPLE)		 -49.30% -153.07% -77.87% -11.21% -29.29% -65.16% -106.46% -133.10% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.61 -12 -8.65 -7.50 -16 -21 -23 -12 -5.24 -5.20 -7.68
NOPAT Margin		 0.00% -2,530.49% -797.68% -368.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -11.06% -27.03% -21.32% -4.31% -5.79% -12.42% -23.02% -21.90% -11.43% -16.67% -20.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -92.05% -37.79% -31.83% -48.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 659.10% 350.14% 217.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 3,055.89% 889.40% 407.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 3,714.99% 1,239.54% 625.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -17 -12 -9.78 -20 -29 -32 -18 -6.91 -6.91 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -17 -12 -9.54 -21 -29 -32 -18 -6.86 -6.84 -10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.92 3.52 7.04 1.12 1.74 1.49 1.27 0.93 0.06 0.08 0.08
Price to Tangible Book Value (P/TBV)		 3.92 3.52 7.04 1.12 1.74 1.49 1.27 0.93 0.06 0.08 0.08
Price to Revenue (P/Rev)		 0.00 83.43 102.46 48.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 50.35 84.95 4.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.17 -1.27 -1.05 -1.05 -1.08 -1.10 -1.15 -1.07 -0.92 -0.79
Leverage Ratio		 1.08 1.25 1.34 1.06 1.06 1.14 1.19 1.21 1.22 1.16 1.16
Compound Leverage Factor		 1.08 1.25 1.34 1.06 1.06 1.14 1.19 1.21 1.22 1.27 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.50 -3.66 10.80 21.35 8.27 0.36 -4.56 -16.05 -16.69 -15.13 -16.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.20 3.44 4.98 33.41 11.02 6.47 6.13 4.76 4.81 7.42 6.55
Quick Ratio		 9.20 3.44 4.98 33.41 11.01 5.98 6.11 4.72 3.95 5.76 3.99
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.51 -8.99 -9.56 -8.41 -12 -24 -22 -15 -7.33 -7.34 -10
Operating Cash Flow to CapEx		 -5,329.56% -303,225.00% -100,558.33% -10,025.56% -124,475.00% -59,743.18% -299,018.18% -462,525.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.03 -127.54
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -9.64 -79.94
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -9.64 -79.94
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.06 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 1.41 4.94 10.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.58 1.79 5.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 259.10 73.84 33.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 259.10 73.84 33.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.28 -4.11 -3.20 -2.29 -5.75 -3.04 -4.43 -1.98 0.11 2.25 4.65
Invested Capital Turnover		 0.00 -0.17 -0.30 -0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.10 -2.83 0.90 0.91 -3.46 2.71 -1.39 2.46 2.08 2.14 2.40
Enterprise Value (EV)		 61 24 92 8.40 46 19 3.88 -2.85 -13 -13 -9.89
Market Capitalization		 84 39 111 99 121 66 39 13 0.76 1.34 1.24
Book Value per Share		 $1.94 $1.00 $1.30 $6.09 $3.32 $2.09 $1.43 $0.54 $0.55 $3.24 $9.54
Tangible Book Value per Share		 $1.94 $1.00 $1.30 $6.09 $3.32 $2.09 $1.43 $0.54 $0.55 $3.24 $9.54
Total Capital		 22 11 16 88 70 44 30 13 14 16 16
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -23 -15 -19 -90 -76 -47 -35 -15 -14 -14 -11
Capital Expenditures (CapEx)		 0.16 0.00 0.01 0.09 0.01 0.04 0.01 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.16 -4.30 -3.69 -2.49 -6.11 -3.39 -4.75 -2.27 -0.02 2.00 4.65
Debt-free Net Working Capital (DFNWC)		 21 11 15 88 69 44 30 12 10 14 16
Net Working Capital (NWC)		 21 11 15 88 69 44 30 12 10 14 16
Net Nonoperating Expense (NNE)		 3.01 5.14 3.64 2.36 4.80 7.62 9.45 5.51 1.67 2.32 2.63
Net Nonoperating Obligations (NNO)		 -23 -15 -19 -90 -76 -47 -35 -15 -14 -14 -11
Total Depreciation and Amortization (D&A)		 0.14 0.21 0.26 0.24 -0.07 0.13 0.16 0.03 0.05 0.07 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -919.70% -340.37% -122.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 2,388.22% 1,410.51% 4,303.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 2,388.22% 1,410.51% 4,303.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $20.25 $19.80 $127.80 $30.00 $8.08 $2.39
Adjusted Weighted Average Basic Shares Outstanding		 740.03K 0.00 0.00 1.40M 1.41M 1.42M 1.67M 140.02K 230.80K 930.82K 4.31M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $20.25 $0.00 $0.00 $30.00 $8.08 $2.39
Adjusted Weighted Average Diluted Shares Outstanding		 740.03K 0.00 0.00 1.40M 1.41M 1.42M 1.64M 139.68K 230.80K 930.82K 4.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $20.25 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 740.03K 0.00 0.00 1.21M 1.41M 1.42M 1.67M 140.02K 420.44K 1.65M 6.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.61 -12 -8.65 -7.50 -16 -21 -23 -12 -5.24 -4.39 -5.96
Normalized NOPAT Margin		 0.00% -2,530.49% -797.68% -368.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -3,607.49% -1,133.55% -479.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.32 -129.49
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.52 -97.21
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.32 -129.49
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.52 -97.21
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Galmed Pharmaceuticals

No quarterly metrics and ratios for Galmed Pharmaceuticals are available.


Financials Breakdown Chart

Galmed Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Galmed Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Galmed Pharmaceuticals' net income were at -$10.31 million at the end of 2025, a 37.1% increase from 2024, and a 2.9% decrease since 2015. View Galmed Pharmaceuticals' forecast to see where analysts expect Galmed Pharmaceuticals to go next.

Galmed Pharmaceuticals' total operating income in 2025 was -$10.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $10.97 million

Over the last 10 years, Galmed Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Galmed Pharmaceuticals' total liabilities were at $2.85 million at the end of 2025, a 30.9% increase from 2024, and a 4.7% increase since 2015.

In the past 10 years, Galmed Pharmaceuticals' cash and equivalents has ranged from $2.02 million in 2022 to $24.16 million in 2018, and is currently $3.99 million as of their latest financial filing in 2025.

Over the last 10 years, Galmed Pharmaceuticals' book value per share changed from 1.94 in 2015 to 9.54 in 2025, a change of 391.5%.


Related Companies

Financial statements for NASDAQ:GLMD last updated on 8/19/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Trump’s new dollar decree
The last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...
Porter & Company | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Every UBI experiment has died the same death, except this one
More than 100 UBI pilots have launched across US cities like Stockton, Denver, and Austin. Nearly all have end...
Freedom Financial | Sponsoredtc pixel
Wall Street priced these two companies backwards
A newly public clean energy company raised nearly 10 billion dollars in the biggest clean energy IPO ever, des...
Behind the Markets | Sponsoredtc pixel